



zymeworks

Zymeworks to Present at the UBS Global Healthcare Conference 2018

May 10, 2018

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming UBS Global Healthcare Conference taking place May 21-23, 2018 in New York, NY, USA.

The Company will present on Monday, May 21, 2018 at 2:00 p.m. ET. Interested parties can access a live webcast of the presentation via a link from Zymeworks' website at <http://ir.zymeworks.com/events-and-presentations>, which will also host a recorded replay available afterwards.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Zymeworks' suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks' lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks' wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20180510005960/en/): <https://www.businesswire.com/news/home/20180510005960/en/>

Zymeworks Inc.

Investor Inquiries:
Ryan Dercho, Ph.D.
604-678-1388

[\[email protected\]](#)

or

Media Inquiries:
Angela Bitting
925-202-6211

[\[email protected\]](#)

Source: Zymeworks Inc.